CeriBell, Inc. (NASDAQ:CBLL) Given Average Rating of “Moderate Buy” by Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $23.20.

CBLL has been the topic of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CeriBell in a report on Monday, April 6th.

CeriBell Trading Down 0.3%

NASDAQ CBLL opened at $21.13 on Tuesday. The company’s fifty day simple moving average is $19.05 and its 200-day simple moving average is $18.08. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. The stock has a market cap of $795.33 million, a P/E ratio of -14.37 and a beta of 0.94.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The business had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. Equities research analysts predict that CeriBell will post -1.44 EPS for the current fiscal year.

Insider Activity at CeriBell

In related news, VP David Foehr sold 4,560 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total value of $81,168.00. Following the sale, the vice president directly owned 17,550 shares of the company’s stock, valued at $312,390. This represents a 20.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the completion of the sale, the chief technology officer directly owned 166,912 shares in the company, valued at $3,097,886.72. This represents a 6.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 130,571 shares of company stock valued at $2,411,026. Insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Several institutional investors have recently added to or reduced their stakes in CBLL. JPMorgan Chase & Co. raised its holdings in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after acquiring an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after purchasing an additional 17,177 shares during the period. New York State Common Retirement Fund raised its holdings in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after purchasing an additional 5,200 shares during the period. Quantbot Technologies LP raised its holdings in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after purchasing an additional 6,401 shares during the period. Finally, Invesco Ltd. acquired a new stake in shares of CeriBell during the second quarter worth $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.